Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,220.00 Price Target at Barclays

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price increased by Barclays from $1,200.00 to $1,220.00 in a report released on Friday, Benzinga reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock.

Several other brokerages have also commented on REGN. Piper Sandler lifted their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the stock an overweight rating in a research report on Friday, July 19th. Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an outperform rating and a $1,150.00 target price for the company. Bank of America lifted their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an underperform rating in a research report on Friday, April 12th. Truist Financial reiterated a buy rating and issued a $1,200.00 target price (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday. Finally, Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating for the company in a research report on Thursday, July 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $1,097.05.

Regeneron Pharmaceuticals Stock Down 1.0 %

NASDAQ REGN traded down $10.95 during mid-day trading on Friday, reaching $1,082.19. 646,247 shares of the company’s stock traded hands, compared to its average volume of 415,793. Regeneron Pharmaceuticals has a 1-year low of $759.15 and a 1-year high of $1,115.00. The company has a fifty day simple moving average of $1,043.43 and a 200-day simple moving average of $982.47. The company has a current ratio of 5.96, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The company has a market cap of $119.25 billion, a price-to-earnings ratio of 31.97, a P/E/G ratio of 2.34 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. As a group, equities research analysts expect that Regeneron Pharmaceuticals will post 37.38 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the sale, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Joseph J. Larosa sold 1,866 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at approximately $41,311,496.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,074 shares of company stock valued at $64,546,123. Corporate insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently modified their holdings of REGN. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $932,571,000. Global Assets Advisory LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $339,594,000. Capital International Investors grew its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Regeneron Pharmaceuticals by 115.2% during the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after buying an additional 195,902 shares in the last quarter. Finally, abrdn plc grew its holdings in shares of Regeneron Pharmaceuticals by 552.8% during the fourth quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after buying an additional 186,215 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.